Skip to content

A verification study of the improving effects of "kibou no meisui" on blood vessel, autonomic, and immune function: an open-label study

A verification study of the improving effects of "kibou no meisui" on blood vessel, autonomic, and immune function: an open-label study - A verification study of the improving effects of "kibou no meisui" on blood vessel, autonomic, and immune function

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000055253
Enrollment
20
Registered
2024-08-16
Start date
2024-08-09
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Japanese

Interventions

Duration: 12 weeks Test food: Kibou no meisui Administration: Take daily whichever amount is greater, your body weight (mL) or your age (mL). Dilute five times with water when drinking. *Daily do

Sponsors

national university corporation Tokushima University
Lead Sponsor
Grace Medical Clinic
Collaborator

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. Japanese 2. Women 3. Individuals aged between 50 and 80 4. Healthy individuals 5. Individuals who have never drunk "kibou no meisui" 6. Individuals who have received vaccination for COVID-19 at least three times

Exclusion criteria

Exclusion criteria: 1. Individuals who are undergoing medical treatment or have a medical history of malignant tumor, heart failure, or myocardial infarction 2. Individuals who have a pacemaker or an implantable cardioverter defibrillator (ICD) 3. Individuals who are currently undergoing treatment for any of the following chronic diseases: cardiac arrhythmia, liver disorder, kidney disorder, cerebrovascular disorder, rheumatism, diabetes mellitus, stroke disorder, dyslipidemia, hypertension, neoplastic disease, hemorrhagic disease, infectious disease, amyotrophy, heart disease, disc herniation, ossification of the posterior longitudinal ligament, spondylosis deformans, spinal stenosis, osteoporosis, atlantoaxial subluxation, unstable spine, scoliosis, spina bifida, spondylolisthesis, or any other chronic diseases 4. Individuals who take "Foods for Specified Health Uses," "Foods with Functional Claims," or other functional foods/beverages on a daily basis 5. Individuals who are currently taking medications (including herbal medicines) and supplements 6. Individuals who are allergic to medicines and foods related to the test food 7. Individuals who are pregnant, lactating, or planning to become pregnant during this study 8. Individuals who suffer from COVID-19 9. Individuals who have been enrolled in other clinical studies within the last 28 days before the agreement to participate in this study or plan to participate in another study during this study 10. Individuals who are smokers 11. Individuals who are judged as ineligible to participate in this study by the physician

Design outcomes

Primary

MeasureTime frame
1. Blood test, vascular age, and vascular aging

Secondary

MeasureTime frame
1. Questionnaires and medical record

Countries

Japan

Contacts

Public ContactMorihiro Kumagai

JES Co., Ltd. Executive Vice President

kuma@j-smc.co.jp03-3364-7407

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026